Do you want to learn more about the impairment of mitochondrial function in drug-induced steatosis, whether it is micro- or microvacuolar, steatohepatitis, or MASLD? Or are you interested in non-mitochondrial mechanisms in drug-induced steatosis?
If you answer positively on any of these questions or have an interest in therapies for the prevention and treatment of drug-induced mitochondrial dysfunction and steatosis or other liver lesions, then the review article published in January 2025 in Clinics and Research in Hepatology and Gastroenterology, might be exactly what you need.
“Mitochondrial dysfunction in drug-induced hepatic steatosis: Recent findings and current concept”, review is co-signed by Annie Borgne-Sanchez, the CEO of Mitologics and Bernard Fromenty, head of the EXPRES team of the Unit of Liver, Metabolisms and Cancer (NuMeCan), at the University of Rennes deals with all these topics at a great level of detail. It follows our latest article published in April 2024 in Toxicological Sciences, the paper Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals.
We’d like to say thanks to Bernard Fromenty, with whom Mitologics has been working since 2009.
This collaboration, part of the project MITOXDRUGS, has been supported by the ANR (Project ANR-16-CE18-0010).
All Mitologics’ scientific publications are listed here, check if you want to learn more.
